This invention relates to novel tetrazolyl-propionamides in which the amide group comprises an aminoazepinone, and related structures, of Formula (I): ##STR00001## or pharmaceutically acceptable salt or prodrug forms thereof, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A.beta.-peptide, thereby resulting in prevention and treatment of the neuropathology associated with production of A.beta.-peptide. More particularly, the present invention relates to the treatment of neurological disorders related to .beta.-amyloid production such as Alzheimer's disease.